How much does tremelimumab cost?

Tremelimumab is a cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blocking human IgG2 monoclonal antibody produced in NS0 cell suspension cultures by recombinant DNA technology. A common clinical preparation in clinical practice is temsitumumab injection, which is a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution, packaged in single-dose vials and diluted for intravenous infusion.

CTLA-4 is a negative regulator of T cell activity. Texitumumab is a monoclonal antibody that binds CTLA-4 and blocks the interaction with its ligands CD80 and CD86, releasing CTLA-4-mediated inhibition of T cell activation. In synergistic mouse tumor models, blocking CTLA-4 activity resulted in reduced tumor growth and increased T cell proliferation in tumors. Temtumumab is indicated for adult patients with unresectable hepatocellular carcinoma (uHCC) in combination with durvalumab and platinum-based chemotherapy for adult patients with metastatic non-small cell lung cancer (NSCLC) without sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumor abnormalities. The exposure-response relationship for its safety and efficacy and the time course of the pharmacodynamic response have not been fully determined.

Tesetumumab is an emerging cancer immunotherapy drug that has not yet been launched in China, so it has not been included in the medical insurance. Domestic patients cannot yet purchase this drug. The U.S. version of temsitumumab’s original drug has been on the market overseas for a short time, and the price is not yet clear. There is currently no known generic version of temsitumumab that has been produced and launched. For specific prices and drug details, please consult Yaode’s medical consultant.